The Hyderabad biotech CA and the DPIIT-ESOP window
Anjali Reddy is thirty-two years old and has been a Chartered Accountant for six years. She works alone in a single-room office on the fourth floor of a glass-fronted building in Hyderabad's Gachibowli — the kind of building where the tenancy is month-to-month, the Wi-Fi password rotates, and the lift sometimes arrives at the fourth floor only after being summoned twice. She chose this over a Big 4 firm not out of rebellion but out of something clearer: a preference for working with founders at the moment they discover what their own company actually owes, rather than at the moment a tax officer has already decided it was owed three years ago.
Her clients are boutique: a genome-sequencing startup called GenSeq, a contract research organisation doing FDA-regulated testing, a biotech incubator, and a string of smaller biotech firms clustered around Hyderabad's Genome Valley. They find her through word of mouth — a founder who knew a founder who mentioned that Anjali Reddy, who does her own filing, answers her phone at 6:30 a.m. and does not bill for the first consultation. She is married, childless by choice, and lives four kilometres away in a flat in Jubilee Hills where she can see the tower of the Birla Mandir. She goes to the ICAI office once a month to sit in the library and read the sector guidance publications as they arrive — a ritual she began in her articleship and has never abandoned.
GenSeq had been one of her clients for eighteen months. The founders were three women: Priya and Meera, who had PhDs in computational genomics from CSIR labs in Delhi, and Nasrin, a former operations manager at an Aurobindo manufacturing facility who understood the commercialisation of biotech science. They had raised a pre-Series A round of ₹4 crore from the Telangana government's biotech fund and a smaller cheque from a Bangalore-based angel investor. Anjali had structured the cap table, filed the 409A valuation, and advised on the company's Section 35(1AB) weighted-deduction eligibility — a tax benefit that would let them claim 150% of their R&D spend as a deduction, capped at 5% of book profit.
What very nearly happened to GenSeq started with a perfectly ordinary email.
🗓️ The annual ritual
The Department for Promotion of Industry and Internal Trade — DPIIT — runs a Startup Recognition program. Every financial year, it announces a window in which Indian startups can apply for formal government recognition. The recognition itself carries tangible benefits: a ten-year income-tax exemption on profits derived from the startup's eligible business, relief from the three-year employment-audit requirement for foreign nationals, and a relaxation on the investment-limit rules for venture capital. For a three-woman genome-sequencing startup in Hyderabad, those benefits are not tokens. They are the difference between reinvesting ₹40 lakh in R&D equipment and sending a cheque to the tax office.
GenSeq's founders had assumed, some months prior, that this had been filed. The assumption rested on a conversation with their company secretary — a Hyderabad CS who maintained compliance for three startups in the Genome Valley corridor. The conversation, as the founders reported it to Anjali, had gone: "We are filing your DPIIT application. We will send you updates." No updates came. The application window remained open. No one asked for it. By May 2026, the application window was six weeks from closing.
Anjali, working with GenSeq on their annual compliance checklist, asked to see the DPIIT acknowledgment receipt. Meera forwarded a screenshot of an email draft, unsent. Not sent to DPIIT. Not submitted. Drafted, saved, forgotten.
- 🗓️
December 2025 — CS engagement
GenSeq's company secretary reports that the DPIIT application will be filed. Founders accept this as done. No written confirmation is requested or provided.
- 📨
Feb–March 2026 — Window remains open
DPIIT Startup Recognition window stays open. GenSeq receives no follow-up communication. No one internally flags the status.
- 🛑
Early May 2026 — Discovery
Anjali asks to see the DPIIT acknowledgment receipt. A screenshot of an unsent draft email is produced. The application was never filed.
- ₹
Mid-May 2026 — Rapid re-filing
Application submitted within 48 hours. DPIIT acknowledgment received. The ten-year tax-exemption window remains open — but the moment nearly passed.
⚠️ What very nearly happened
The complication was not that the DPIIT application was missing. The complication was what the application required, and what it revealed.
DPIIT recognition comes with a condition: the startup must have been incorporated in the last seven years, must derive 75% of its revenue from an eligible business (biotech qualifies), and must not distribute profits above a certain threshold to shareholders. It also requires that the company not have a shareholding structure where an individual holds more than 10% of equity while simultaneously holding equity in a competing business. And it requires a formal board resolution confirming that the company meets these criteria.
When Anjali dug into the filings, she discovered that GenSeq's board had never passed such a resolution. The company secretary had drafted resolutions related to fundraising and appointment of directors, but no DPIIT-specific confirmation. This was a gap. It could be remedied, but it would require a board meeting, a resolution, and a new filing.
There was a second gap. GenSeq was in the process of structuring an ESOP — an Employee Stock Option Plan — to grant shares to early employees at a discount. This is standard practice for startups seeking to conserve cash while attracting talent. The ESOP would be held in trust, with an employee-appointed trustee managing allocation and exercise. Anjali had advised on the structure. What she had not yet verified was whether the ESOP trust, once formally created, would be considered a related-party entity under SEBI rules, and if so, whether that status would disqualify GenSeq from the Section 35 weighted-deduction benefit — the 150% R&D tax deduction that was, in financial terms, one of the company's most valuable assets.
The agent's role, at this point, was to verify what was actually true, rather than what the founders believed to be true.
"ఈ ఫైలింగ్ విషయంలో, నాకు విశ్వాసం చేసుకోవడానికి కంటే, నిర్థారణ చేసుకోవడం ఎక్కువ ఖరీదు వస్తుంది."— In a filing matter, I pay more to verify than to assume.
🌗 What changed
Anjali's first instinct was to open the ICAI Knowledge Portal and scroll through the latest biotech sector guidance. She had been reading these notices for six years, and she knew the pattern: guidance arrived in clusters, usually six months after a problem became common. What she was searching for was any notice that addressed whether an ESOP trust constitutes a related-party entity for purposes of Section 35 deduction eligibility.
She found nothing dated later than 2024. The last notice suggested that ESOP trusts, when structured correctly with independent trustees, were generally not treated as related parties — but it was not a definitive ruling. It was a suggestion. For a question worth ₹20–30 lakh in annual tax benefits, a suggestion was not enough.
She pulled up the MCA e-Gazette portal and searched GenSeq's filings. She found board resolutions approving the ESOP structure, the equity cap table, and the trustee appointment. What she did not find was the formal ESOP trust deed itself — the document that would actually establish the trust, list its beneficiaries, and define the trustee's powers. The trust had been drafted. It had not been filed.
She sat back at her desk. GenSeq's founders believed they had three things in place: a DPIIT application, an ESOP trust deed, and clarity on Section 35 eligibility. They actually had none of the three in their formal state. The belief was reasonable. It was just wrong.
She called Meera at 7:45 a.m.
"మీరు అనుకున్నట్టుగా DPIIT ఫైలింగ్ లేదు, ESOP ట్రస్ట్ డీడ్ ROC లో ఫైల్ కాలేదు — ఈ రెండూ నెమ్మదిగా ఆ పాయింట్ వద్ద ఉన్నాయి. నీకు ఒక AI ఏజెంట్ చూపెట్టాను, అతను నిన్ను స్పష్టంగా చెప్పినట్లు చెప్పుకోనీయు."
(You do not have the DPIIT filing as you believed, and the ESOP trust deed is not filed with the ROC — both are at the point of being drafted but not submitted. I want you to talk to an AI agent who will tell you exactly what is missing, and in what sequence.)
Meera agreed, cautiously. Anjali opened the agent interface on her laptop, set it to Telugu, and began a session with GenSeq's background uploaded: the 409A valuation, the board resolutions, the equity cap table, the ICAI sector guidance excerpts, and the MCA search results showing what had been filed and what had not.
The agent's first message was methodical:
"GenSeq యొక్క మూడు వేర్వేరు సమస్యలు ఉన్నాయి, కానీ సిరీస్లో ఉన్నాయి. మొదటిది: DPIIT బోర్డ్ రెజోలిউషన్ లేదు. రెండవది: ESOP ట్రస్ట్ డీడ్ ఫైల్ కాలేదు. మూడవది — ఇది సమాధానం కోసం నిర్థారణ అవసరం — Section 35 వెయిటెడ్ డెడక్షన్ ఎలిజిబిలిటీ ఉంటుందా ఒకసారి ESOP ఉంటే? ICAI సెక్టర్ నోటీస్ సాధారణంగా చెస్తే, సరిగా నిర్మితమైన ESOP ట్రస్ట్తో, సంబంధం లేని సంస్థ. కానీ నీకు ఆఫీస్ ఆఫ్ ప్రిన్సిపల్ CIT లో అడానుంచవలసిందే."
(GenSeq has three separate problems, but they are sequential. First: there is no DPIIT board resolution. Second: the ESOP trust deed is not filed. Third — and this requires verification — will GenSeq retain Section 35 weighted-deduction eligibility once the ESOP is in place? The ICAI sector notice suggests that, with a correctly structured ESOP trust with an independent trustee, the ESOP would not be a related party. But you should seek advance clarity from the Office of the Principal CIT.)
This distinction mattered. The agent was not saying the problem was solved. It was saying that one part of the problem — the ESOP trust relationship to Section 35 — could not be solved by reading guidance. It required an active clarification from the tax authority itself.
Anjali, on a Monday morning, sent a detailed letter to the Office of the Principal CIT, Hyderabad, seeking an advance confirmation under Section 288B(1) of the Income Tax Act. The letter laid out GenSeq's structure, the 150% R&D deduction claim, and a specific question: "If GenSeq establishes an ESOP trust with an independent, non-shareholder trustee, will the trust be treated as a related-party entity for purposes of Section 35(1AB) weighted-deduction eligibility?"
The reply came eleven days later. The answer: no, the ESOP trust would not be treated as a related party, provided the trustee was demonstrably independent and annual ESOP transactions were disclosed in the company's audit schedule.
The DPIIT board resolution was drafted and passed at an emergency board meeting the same week. The ESOP trust deed was finalized and filed with the Registrar of Companies within ten days. Both confirmations were uploaded to the DPIIT portal. The application was submitted on a Friday afternoon. The acknowledgment arrived the following Tuesday.
Anjali made a note in her practice journal: "GenSeq — DPIIT + ESOP + Section 35 verification complete. Window closed 47 days after initial discovery of non-filing. All three components now in place."
🧭 Why we built it
There are approximately 80,000 recognized startups registered with DPIIT. Of these, roughly 12,000 are biotech or biomedical companies. The majority will never discover that the DPIIT filing they believe to have been completed was actually drafted and forgotten — because their accountants do not routinely audit what has and has not been actually submitted to government portals. The assumption is that if the CS said it was done, it was done. The assumption is reasonable. It is also wrong with sufficient frequency that the gap creates serious financial exposure.
What makes Anjali's situation particular — and what the agent's role was to address — is the layering of the problems. DPIIT eligibility depends on a clean shareholding structure, which depends on the ESOP trust not being a related party, which depends on clarity from the tax authority. Each of these facts requires verification from a different source. A human CA can verify one or two. Verifying all three, in sequence, and catching the order in which they must be resolved, is what creates the gap in which problems remain unfixed.
Private-sector startups in India's biotech hubs do not have a government compliance officer, the way Central Government establishments do. They have a CS — busy with three companies, checking email at 9:30 p.m., forgetting which draft was sent to which portal. They have a CA — six years in, one room in Gachibowli, reading the ICAI notices by hand every month because it is still the most reliable way to catch the sector guidance as it arrives. What they do not have is someone who sits next to the CS and the CA, cross-references the MCA filings with the ICAI notices with the DPIIT portal, and says: you believe this has been filed, but it has not been actually submitted. Here is the sequence in which the three problems must be solved. Here is how long it will take. Here are the risks if we wait.
What it does
- 🔍Cross-referenced MCA filed documents with founder assumptions, identifying that DPIIT application was drafted but never submitted, and ESOP trust deed was drafted but never filed.
- 🗂️Matched ICAI sector guidance on ESOP-related-party treatment with GenSeq's specific structure, flagging that advance tax authority confirmation was needed.
- 📞Sequenced the three problems in the order they must be solved: DPIIT resolution first, then ESOP trust deed filing, then Section 35 verification — not as simultaneous tasks.
What it does not do
- 🔒Never accessed GenSeq's bank accounts, tax credentials, or password-protected portals — Anjali herself logged into every filing interface and confirmed each submission.
- 💳Never filed any document with MCA or DPIIT — the agent identified what was missing, but Anjali made the decision to file, and the trustee made the decision to sign.
- ✅Never told GenSeq that the Section 35 benefit was certain — it flagged that tax-authority confirmation was necessary, and the confirmation was sought proactively.
We built the agent for this specific moment: the founder who believes the filing is complete but the file has never actually been submitted, and the CA who is trying to catch the gap before the window closes. It is a narrow window. The DPIIT application window opens once a year and closes after four months. The ESOP benefit window — the period in which employees can be granted options at fair value without tax consequences — does not have a formal close, but it does have a practical one: once employees exercise, the window for restructuring becomes expensive. The Section 35 deduction window is a financial-year calendar. The cost of discovering all three problems at once is a missed opportunity window that does not reopen.
🌱 What we hope happens
Meera sent Anjali a message in the second week of May, after the DPIIT acknowledgment arrived. She said: "I was very angry when I discovered we were not filed. Then I realized I was not angry at anyone — just angry at the gap between what I thought was true and what was actually true. The agent and you together closed that gap."
Which is what we hoped this would do. Not to replace the CS or the CA, but to sit between them — cross-checking the assumption against the portal, reading the ICAI notice against the filed structure, asking the specific question that will force an advance clarification to be sought rather than left floating.
There is a particular kind of missed opportunity in Indian startup life that is easy to miss because no one is acting badly. The CS meant to send the email. The email was drafted. The CA asked to see the receipt. The receipt did not exist. No one made an error, in the sense of doing something wrong. Everyone did their job. The gap is in the structure of work that happens on assumption rather than verification. For the CAs in Hyderabad who are awake at 6:30 a.m. reading the ICAI notices, and the CSes managing three startups, and the founders trying to decode the sequence of three separate compliance problems, this product is free at gabforge.in. We have native Telugu, Tamil, Kannada, Malayalam, and English. The agent can read ICAI guidance, cross-reference MCA filings, and tell you whether the file you believe you submitted has actually been submitted. Set it up on a laptop in your office. It will not replace your CA. It will sit next to your CA and read the portal with them — so that the draft email stays draft, but the DPIIT window does not close on the assumption that it was sent.